A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma

Lilly

Status and phase: Withdrawn; Phase 2; Phase 1

Conditions: Hepatocellular Carcinoma

Treatments: Drug: LY2181308

Study type: Interventional

Funder types: Industry

Identifiers

NCT00415155

H8Z-MC-JACS

10460

Details and patient eligibility

About

The primary objective of this study is to estimate the time to progressive disease for patients with advanced hepatocellular cancer who receive LY2181308.

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with hepatocellular cancer
• Discontinued all previous therapies
• At least 18 years of age

Exclusion criteria

• Have other treatment options that are potentially curative or effective--such as surgical resection, liver transplant or percutaneous ablation, and/or transcatheter arterial embolization.
• Transplanted liver
• HIV positive
• More than 2 previous systemic chemotherapy treatments

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

60 participants in 1 patient group

A

Experimental group

Treatment:

Drug: LY2181308